A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Clinical trial NCT06567782 · RECRUITING

Trial details

NCT number: NCT06567782
Sponsor: GlaxoSmithKline
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neoplasms, Colon

Start date: 2025-02-18
Primary completion: 2026-11-23
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.